

Key Information Document

Purpose

This document provides you with key information about this investment Product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this Product and to help you compare it with other products.

Product

Product Name:	LIMMAT CAPITAL SICAV – LC Equity Fund (UCITS) (the "Product")
Product Identifier:	ISIN: LU1749419120
Product Manufacturer:	Limmat Capital Alternative Investments AG ("We")
Contact Details:	Website: limmat.capital Call +41 44 204 1919 for more information
Competent Regulatory Authority:	This Product is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier. ONE Fund Management S.A., as management company is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier. Limmat Capital Alternative Investments AG is authorized in Switzerland and regulated by the Swiss Financial Market Supervisory Authority who is supervising Limmat Capital Alternative Investments AG in relation to this Key Information Document.

This document is accurate as of 1 January 2023.

What is this Product?

Objectives:

The investment objective of the Product is to achieve long-term capital appreciation through investing in primarily European and American equities and constructing a portfolio with a reasonable risk diversification.

The investment process comprises a framework combining discretionary investment decision-making with proprietary and third-party quantitative and qualitative tools, applications, and models. When identifying possible investment opportunities, the Fund Manager takes both bottom-up research findings and macro analysis into consideration.

The Fund Manager will select investments opportunistically and not defined by predetermined allocation levels to sectors or geographical locations. Depending on the relative attractiveness of an opportunity and changes in market volatility, the Fund Manager may adjust portfolio weightings. The Product may use derivatives, including over-the-counter swap transactions, options, warrants, futures and forward contracts to achieve the investment objective.

The Product will not focus on any specific country or sector. Leverage may be deployed through derivatives.

The return of the Product is also related to the recommended holding period and risk and reward profile.

For further information, please see the "Investment Objective" and "Investment Policy" sections of the Product's supplement to the prospectus.

Unless otherwise defined in this document, all words and expressions defined in the Product's current prospectus shall have the same meaning herein.

Term:

The Product has no maturity date.

Benchmark:

The Product is actively managed and is not managed in reference to a benchmark.

Type:

This Product is a Share class of LIMMAT CAPITAL SICAV – LC Equity Fund (UCITS) (the "Sub-Fund"), a sub-fund of LIMMAT CAPITAL SICAV (the "Fund"), a UCITS fund organised as a public limited company and qualifying as an investment company with variable capital with multiple sub-funds.

The performance of this Product will depend on the performance of the portfolio of investments of the Sub-Fund, as further described in the section "Objectives" of this document.

Intended Retail Investor:

This Product is suitable for:

- Investors seeking growth through an actively managed fund invested across different types of assets.
- Investors with a knowledge level of a basic, informed and advanced investor.
- Retail investors who rely on investment advice and portfolio management services.
- Investors who have an investment horizon of 5 years or more.
- Investors who are able to bear the loss of their entire investments due to market risks as described in the section "What are the risks and what could I get in return?" below.

Depositary:

Elavon Financial Services DAC, Luxembourg Branch, 4, rue Albert Borschette L-1246 Luxembourg Grand Duchy of Luxembourg (the "Depositary").

Distribution Policy:

Your Shares are non-distributing (i.e., any income arising from your Shares will be included in their value).

Dealing:

Investors can redeem and subscribe for Shares in the Product on demand on any day on which banks are open for business in Luxembourg or the next following Business Day if such day is not a Business Day.


The assets and liabilities of the Sub-Fund are segregated from the other sub-funds of the Fund by law. However, the assets and liabilities of your Shares are not segregated from the assets and liabilities of the other classes of Shares of the Sub-Fund.

You are able to convert your Shares into other classes of Shares in sub-funds of the Product. Further information about how to do this can be found in the Product's prospectus.

The Product's latest prospectus, annual and semi-annual reports, updated KIDs, other product information, including the prices of the Shares are available, free of charge, in English at <http://www.fundinfo.com>. Such prospectus and reports are prepared at the level of the Product as a whole.

What are the risks and what could I get in return?

Risk Indicator



The risk indicator assumes you keep the Product for 5 years.



The summary risk indicator is a guide to the level of risk of this Product compared to other products. It shows how likely it is that the Product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this Product as 6 out of 7, which is the second highest class. This rates the potential losses from future performance at a high level, and poor market conditions are very likely to impact our capacity to pay you.

Be aware of currency risk if your reference currency differs from the currency of the Product. You may receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.

Please refer to the Product's prospectus for a full list of risks which can affect the overall Product value.

This Product does not include any protection from future market performance so you could lose some or all of your investment. If we are not able to pay you what is owed, you could lose your entire investment.

Performance Scenarios

The figures shown include all the costs of the Product itself but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back. What you will get from this Product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average and best performance of the Product and/or its benchmark over the last 10 years. Markets could develop very differently in the future. The stress scenario shows what you might get back in extreme market circumstances.

Recommended Holding Period		5 years		
Example Investment		EUR 10,000		
Scenarios		If you exit after 1 year	If you exit after 3 years	If you exit after 5 years (Recommended Holding Period)
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.			
Stress	What you might get back after costs Average return each year	EUR 5,022 -49.78%	EUR 8,725 -12.75%	EUR 9,115 -8.85%
Unfavourable	What you might get back after costs Average return each year This scenario occurred between 01/2018 and 12/2022	EUR 8,212 -17.88%	EUR 5,537 -17.88%	EUR 3,734 -17.88%
Moderate	What you might get back after costs Average return each year This scenario occurred between 04/2017 and 03/2022	EUR 10,347 3.47%	EUR 11,079 3.47%	EUR 11,862 3.47%
Favourable	What you might get back after costs Average return each year This scenario occurred between 02/2014 and 01/2019	EUR 11,421 14.21%	EUR 14,899 14.21%	EUR 19,435 14.21%

What happens if LIMMAT CAPITAL SICAV is unable to pay out?

You are not covered by any investor compensation or guarantee scheme. To protect you, your assets are held with a separate company, the Depositary. While you will not face a financial loss should we default, in the event of the Depositary's default you may suffer a financial loss. This risk is mitigated as the Depositary is required to segregate its own assets from the assets of the Fund. However, the risk does still exist and you could lose your entire investment.

What are the costs?

The person advising on or selling this Product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Table 1: Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the Product and how well the Product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods. We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the Product performs as shown in the moderate scenario.
- EUR 10,000 is invested.

	If you exit after 1 year	If you exit after 3 years	If you exit after 5 years
Total Costs	EUR 289	EUR 593	EUR 895
Annual Cost Impact (*)	2.89%	3.03% each year	3.02% each year

* This illustrates how costs reduce your return each year over the holding period. For example, it shows that if you exit at the recommended holding period your average return per year is projected to be 6.50% before costs and 3.47% after costs.

What are the costs? (continued)

Table 2: Composition of costs

One-off costs upon entry or exit		Impact on return if you exit after one year
Entry costs	We do not charge an entry fee for this Product.	EUR 0
Exit costs	We do not charge an exit fee for this Product.	EUR 0
Management fees and other administrative or operating costs	2.72% of the value of your investment per year. This is an estimate based on actual costs over the last year.	EUR 272
Transaction costs	0.15% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the Product. The actual amount will vary depending on how much we buy and sell.	EUR 15
Performance fees (and carried interest)	We take performance fees from your investment of 5% of the outperformance against the High Water Mark. The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years.	EUR 3

How long should I hold it and can I take money out early?

Recommended holding period: 5 years

The Product has no required minimum holding period but is designed for long term investments; you should be prepared to stay invested for at least 5 years. However, you can redeem your investment without penalty at any time during this period, or hold the investment longer. The impact of cashing in early could result in a lower return.

How can I complain?

You can send your complaints to the Product's Initiator at Limmat Capital Alternative Investments AG, Attention: Complaints Handling Officer at Riesbachstrasse 57, 8008 Zurich, Switzerland or by e-mail to contact@limmat.capital. Details of the Initiator's complaints handling policy may be found on <http://limmat.capital/>.

If you have a complaint about the person that advised you about this Product, or who sold it to you, they will tell you where to complain.

Other relevant information

The Product's past performance for up to the last 10 years and the previously published performance scenario information is available online at <http://www.fundinfo.com>.

The Product's representative in Switzerland is Credit Suisse Funds AG, Uetlibergstrasse 231, 8045 Zurich, Switzerland. The Product's paying agent in Switzerland is Credit Suisse (Schweiz) AG, Paradeplatz 8, 8001 Zurich, Switzerland. The prospectus, the Key Information Documents, the articles of incorporation as well as the annual and semi-annual reports of the Fund may be obtained free of charge from the Product's representative.